HARROWCatch this wave 3. I think we are almost finished wave 2 wich is mostly the most extreme. So now i expect the wave 3 is going to start.
HROW trade ideas
HROW: Can you guess what this pattern is called?See if you can guess it correctly. Earnings on 11/13
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fundamentals and technicals both align for a sharp move to the upside.
Over the short-term HROW may retest the trend channel breakout around the $17 region. If it holds, which I expect, I believe we could reach a triple-digit share price in short-order, potentially within 18-months, which would be a 500%+ return from today's share price of $19.50.
My personal price target is $150/share by end of year 2025.
HROW: Eye Spy A BottomHROW with a nice impulsive, 5-wave move off the low. HROW needs to hold the 0.618 retracement ($18.75) on this pull back, followed by a rally above the $19.95 local peak set today for further confirmation. Very bullish on the long-term prospects of this ticker.
HROW pull back - thoughts?Bounce off of 100 SMA, 2 long bullish candles with lots of volume, plus sound fundamentals. Any thoughts?
HROW - Long Setup Flag Setup with 2020 Insider Buying. Possible entry here or above 8.44., Stop signal 7.83, First target 9.23. 2nd Target Momentum.
Short Term Rise before head and shoulders completion?I see a short term rise in HROW as our current right shoulder of what looks to be a weekly head and shoulders hit a 61.8% Fibonacci retracement level with Stochastic RSI being as oversold as our last oversold areas. I drew two potential rises using some bear rally based Fibonacci Retracments, I feel we will follow the trajectory towards the one that overlaps with the $5.00 Psych Resistance before continuing our decent towards $2.50 to $3.00
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and exchanged no money. In other words, Harrow got off scot-free and will no longer incur legal fees related to the case. This is great news, so it's surprising that the stock is down, especially when the market as a whole is up. Perhaps Harrow will get a boost if some news agencies pick up the story. In the meantime, Harrow is approaching support at about $5. I picked up a few shares at $5.25 and will look to buy more at $5.
Harrow Health has a 9.4/10 Equity StarMine Summary Score and is rated undervalued (73/100) by S&P Capital IQ.
